Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Daily News

Optimal Care Reported in Less Than Half of Adults With ASCVD

Yael L. Maxwell

December 05, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

Shelley Wood

June 22, 2021

News Daily News

Colchicine in the Crosshairs for Its High US Cost

Caitlin E. Cox

December 01, 2020

News Daily News

Thrombotic Events Frequent Among COVID-19 Patients in ICUs

Michael O'Riordan

October 27, 2020

A secondary analysis from ASPREE sets up two large RCTs testing statins in an elderly primary-prevention population.

News Daily News

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

Michael O'Riordan

July 06, 2020

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Daily News

Remdesivir Study for COVID-19 Yields Positive Top-line Results

Michael O'Riordan

April 29, 2020

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Daily News

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Michael O'Riordan

March 01, 2019

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

Shelley Wood

October 31, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Advertisement

Statins Effective For Primary Prevention in Old and Very Old

Optimal Care Reported in Less Than Half of Adults With ASCVD

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

Colchicine in the Crosshairs for Its High US Cost

Thrombotic Events Frequent Among COVID-19 Patients in ICUs

Statins Cut CV Risk but Don’t Boost Disability-Free Survival in Healthy Elderly

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Remdesivir Study for COVID-19 Yields Positive Top-line Results

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

ISCHEMIA Patients: High Rates of Severe-to-Moderate Ischemia, Multivessel CAD

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

TCTMD’s Top 10 Most Popular Stories for October 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content